A Dose Selection Trial of CKD-330 in Patients With Essential Hypertension

Inclusion Criteria: * Age of 18 or above * Essential hypertension with 90mmHg ≤ mean sitDBP ≤ 115mmHg on target arm at Visit 3 * Ability to provide written informed consent Exclusion Criteria: * nean sitDBP ≥ 116mmHg or mean sitSBP ≥ 200mmHg at Visit 1, Visit 2, Visit 3 * The change of mean sitDBP ≥ 10mmHg or mean sitSBP ≥ 20mmHg on target arm at Visit 1 * Known or suspected Stage 2 Hypertension (aortic coarctation, Primary hyperaldosteronism, renal artery stenosis, pheochromocytoma) * Patients with congestive heart failure(NYHA class III\~IV), ischemic heart disease, cardiomyopathy, heart valve disorder, arrhythmia, coronary artery bypass graft * History of cerebrovascular disease as cerebral infarction, cerebral hemorrhage within 6 months * Type I Diabets Mellitus, Type II Diabetes Mellitus with HbA1c \> 8% * History of severe or malignant retinopathy * AST/ALT \> UNL \* 2, Serum Creatinine \> UNL \* 1.5, K \> 5.5mEq/L * Patients with acute or chronic inflammatory status, autoimmune disease * Patients who need to take antihypertensive drug besides Investigational products * Patients must be treated with medications prohibited for concomitant use during study period * Hypersensitive to Candesartan/Amlodipine or other dihydropyridine drugs * Hereditary angioedema or history of angioedema related to ACE inhibitor or angiotensin II receptor blockers * History of malignant tumor within 5 years * Patients who are dependent on drugs or alcohol * History of disability to drug absorption, active inflammatory bowel syndrome with 12months, impaired pancreatic function, GI bleeding, obstructions of urinary tract * Patients treated with other investigational product within 4 weeks at the time concents are obtained * Women with pregnant, breast-feeding * Not eligible to participate for study at the discretion of investigator